Takahiro Maeda

I’ve decided to move to Bluesky. You can find me here: @tmhemonc.bsky.social. See you there!”

FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation fda.gov/drugs/resource…

Couldn't have made a better choice! Congrats Ivan!

Confident HbF induction will occur, but curious about its effects on erythroid differentiation (PMID: 19853566), lymphoid/HSC fate (PMID: 17495164, 23134786), and humoral immunity (PMID: 21646720), given phenotypes observed in Zbtb7a KO mouse models.

Exciting news about the Pokemon degrader !(ash.confex.com/ash/2024/webpr…)—Phase 1/2a trial is underway !!(NCT06481306)

We're headin' to the World Series. #RepBX

Additionally, Ruxolitinib reduces p-STAT5 but fails to shut down the RAS and mTOR pathways, which are essential for cell survival (ashpublications.org/blood/article/…). We should await the results of trials like NCT02723994 regarding Ruxolitinib’s efficacy in CRLF2-r ALL. 2/2

Of note, while high p-STAT5 levels indicate JAK-STAT activation, this does not necessarily mean that the JAK-STAT axis is crucial for the fitness of CRLF2-r ALL cells. Our CRISPR functional screens have shown that STAT5 and STAT3 are dispensable in CRLF2-r ALL cells. 1/n

ちなみに昨年のプログラムはこちら：conferences-on-demand.faseb.org/do/10.1096/HM2…

造血器腫瘍分野の基礎研究でおすすめの学会です（2年に１度）。ボストン郊外に5日間ほどこの分野のtop scientistsと缶詰になるので、否が応でも交流が広がります。人脈を拡げる絶好の機会です。ボストンのベストシーズンでもあります。毎回日本人のプレゼンスがないので是非！events.faseb.org/event/hematolo…

Sergei and I are excited to continue the tradition of exceptional scientific and career development sessions at the 2025 FASEB Meeting! There will also be lots of time for informal discussions, networking, and collaboration, making this a great meeting for trainees!!

There has been confusion over mitochondrial mutation detection, consensus variant calling, and lineage tracing in single cells. Here, we detail how ReDeeM addresses these challenges, improving detection of mtDNA mutations by 10-fold and lineage tracing. Led by @chenweng1991 and @JswLab, we now constructively address concerns raised: biorxiv.org/content/10.110… Stay tuned for 🧵 from Chen. #genomics #mitochondria #singlecell

日本血液学会/日本臨床腫瘍学会共催 白血病ゲノム医療教育事業オンラインセミナー 「AML診療におけるMRDの意義」 締切間近です。みなさんRTお願いします。 申し込みはこちらから：entry.convention.co.jp/f-system3/view…

大塚製薬の遺伝子パネル検査「ヘムサイト解析プログラム」承認へ　薬審・プログラム医療機器調査会が了承 mixonline.jp/Default.aspx?t…

Genome-wide CRISPR/Cas9 screens identify the mTORC1 pathway as crucial for B-ALL cell sensitivity to dexamethasone. ow.ly/324650SMLLq #lymphoidneoplasia #acutelymphocyticleukemia #basicmechanismsofneoplasia

Estimating the probability of disease for people carrying a genetic variant - known as penetrance - is empowered by large population cohorts, but *very* easy to screw up. So @carolinefwright and friends (including me) explain how to do it right.

@bloodgenes Congrats Vijay!

I am tremendously honored to join this amazing cohort of @HHMINEWS Investigators! I am incredibly fortunate to have worked with incredible people in our laboratory and excited for all that we will be able to do in the coming years!

Congrats Justin and team! Yes just in time:-) !

@TaylorJ_MD Thank you, Justin!

@TMHemOnc Congratulations Takahiro and Tatsuya!

Our paper on the biomarker of selinexor (XPO1 inhibitor, FDA approved for R/R MM and DLBCL) sensitivity has been published online in Leukemia (rdcu.be/dNofH). Via CRISPR dropout screens, we found that DDX19 homologue dosage is key for selinexor sensitivity.

This work has been primarily done by Tatsuya Terasaki, M.D., Ph.D. candidate. Congratulations Tatsuya!

Next questions are: • Is there a DDX19B-low T-ALL subset among human T-ALL cases? • Is DDX19 a new drug target for hematological malignancies?